Sylvain Auvity, Bala Attili, Fabien Caillé, Maud Goislard, Jérôme Cayla, Françoise Hinnen, Stéphane Demphel, Vincent Brulon, Michel Bottlaender, Claire Leroy, Guy Bormans, Bertrand Kuhnast, Marie-Anne Peyronneau
{"title":"新型大麻素 2 受体 (CB2R) 放射配体--(Z)-N-(3-(2-(2-[18F]氟乙氧基)乙基)-4,5-二甲基噻唑-2(3H)-亚基)-2,2,3,3-四甲基环丙烷-1-甲酰胺的临床前 PET 成像和代谢转化评估","authors":"Sylvain Auvity, Bala Attili, Fabien Caillé, Maud Goislard, Jérôme Cayla, Françoise Hinnen, Stéphane Demphel, Vincent Brulon, Michel Bottlaender, Claire Leroy, Guy Bormans, Bertrand Kuhnast, Marie-Anne Peyronneau","doi":"10.1021/acsptsci.4c00348","DOIUrl":null,"url":null,"abstract":"We have previously developed seven fluorinated analogues of A-836339 as new PET tracers for cannabinoid type 2 receptor (CB<sub>2</sub>R) imaging, among which (<i>Z</i>)-<i>N</i>-(3-(2-(2-[<sup>18</sup>F]fluoroethoxy)ethyl)-4,5-dimethylthiazol-2(3<i>H</i>)-ylidene)-2,2,3,3-tetramethylcyclopropane-1-carboxamide ([<sup>18</sup>F]FC0324) displayed high affinity and selectivity for CB<sub>2</sub>R in healthy rats. In the present study, we have further evaluated the imaging and metabolic properties of [<sup>18</sup>F]FC0324 in a rat model of human CB<sub>2</sub>R overexpression in the brain (AAV-<i>h</i>CB<sub>2</sub>) and in non-human primates (NHPs). Autoradiography with AAV-<i>h</i>CB<sub>2</sub> rat brain sections exhibited a signal of [<sup>18</sup>F]FC0324 8-fold higher in the ipsilateral region than in the contralateral region. Blocking with NE40, a CB<sub>2</sub>R-specific agonist, resulted in a 91% decrease in the radioactivity. PET experiments showed a signal 7-fold higher in the ipsilateral region, and the specificity of [<sup>18</sup>F]FC0324 for <i>h</i>CB<sub>2</sub>R in vivo was confirmed by the 80% decrease after blocking with NE40. In NHPs, brain time-activity curves displayed a fast and homogeneous distribution followed by a rapid washout, in accordance with the low amount of CB<sub>2</sub>Rs in healthy brain. Whole-body PET-CT suggested a high and specific uptake of the radiotracer in the spleen, a CB<sub>2</sub>R-rich organ, and in the organs involved in metabolism and excretion, with a low bone uptake. In vitro metabolism with monkey liver microsomes (MLMs) led to the formation of six main hydroxylated metabolites of FC0324. Five of them were produced by human liver microsomes, being much less active than MLMs. In vivo, in NHPs, the main radiometabolite was likely to result from further oxidation of hydroxylated compounds, and parent [<sup>18</sup>F]FC0324 accounted for 8 ± 3% of plasma radioactivity (at 120 min p.i.) with a low level of potential interfering radiometabolites. Furthermore, this metabolism should be significantly reduced in humans due to species differences. In conclusion, [<sup>18</sup>F]FC0324 appears to be a promising candidate for further human studies with suitable kinetics, selectivity, and metabolic profile for CB<sub>2</sub>R PET imaging.","PeriodicalId":501473,"journal":{"name":"ACS Pharmacology & Translational Science","volume":"9 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Translational Preclinical PET Imaging and Metabolic Evaluation of a New Cannabinoid 2 Receptor (CB2R) Radioligand, (Z)-N-(3-(2-(2-[18F]Fluoroethoxy)ethyl)-4,5-dimethylthiazol-2(3H)-ylidene)-2,2,3,3-tetramethylcyclopropane-1-carboxamide\",\"authors\":\"Sylvain Auvity, Bala Attili, Fabien Caillé, Maud Goislard, Jérôme Cayla, Françoise Hinnen, Stéphane Demphel, Vincent Brulon, Michel Bottlaender, Claire Leroy, Guy Bormans, Bertrand Kuhnast, Marie-Anne Peyronneau\",\"doi\":\"10.1021/acsptsci.4c00348\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"We have previously developed seven fluorinated analogues of A-836339 as new PET tracers for cannabinoid type 2 receptor (CB<sub>2</sub>R) imaging, among which (<i>Z</i>)-<i>N</i>-(3-(2-(2-[<sup>18</sup>F]fluoroethoxy)ethyl)-4,5-dimethylthiazol-2(3<i>H</i>)-ylidene)-2,2,3,3-tetramethylcyclopropane-1-carboxamide ([<sup>18</sup>F]FC0324) displayed high affinity and selectivity for CB<sub>2</sub>R in healthy rats. In the present study, we have further evaluated the imaging and metabolic properties of [<sup>18</sup>F]FC0324 in a rat model of human CB<sub>2</sub>R overexpression in the brain (AAV-<i>h</i>CB<sub>2</sub>) and in non-human primates (NHPs). Autoradiography with AAV-<i>h</i>CB<sub>2</sub> rat brain sections exhibited a signal of [<sup>18</sup>F]FC0324 8-fold higher in the ipsilateral region than in the contralateral region. Blocking with NE40, a CB<sub>2</sub>R-specific agonist, resulted in a 91% decrease in the radioactivity. PET experiments showed a signal 7-fold higher in the ipsilateral region, and the specificity of [<sup>18</sup>F]FC0324 for <i>h</i>CB<sub>2</sub>R in vivo was confirmed by the 80% decrease after blocking with NE40. In NHPs, brain time-activity curves displayed a fast and homogeneous distribution followed by a rapid washout, in accordance with the low amount of CB<sub>2</sub>Rs in healthy brain. Whole-body PET-CT suggested a high and specific uptake of the radiotracer in the spleen, a CB<sub>2</sub>R-rich organ, and in the organs involved in metabolism and excretion, with a low bone uptake. In vitro metabolism with monkey liver microsomes (MLMs) led to the formation of six main hydroxylated metabolites of FC0324. Five of them were produced by human liver microsomes, being much less active than MLMs. In vivo, in NHPs, the main radiometabolite was likely to result from further oxidation of hydroxylated compounds, and parent [<sup>18</sup>F]FC0324 accounted for 8 ± 3% of plasma radioactivity (at 120 min p.i.) with a low level of potential interfering radiometabolites. Furthermore, this metabolism should be significantly reduced in humans due to species differences. In conclusion, [<sup>18</sup>F]FC0324 appears to be a promising candidate for further human studies with suitable kinetics, selectivity, and metabolic profile for CB<sub>2</sub>R PET imaging.\",\"PeriodicalId\":501473,\"journal\":{\"name\":\"ACS Pharmacology & Translational Science\",\"volume\":\"9 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Pharmacology & Translational Science\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1021/acsptsci.4c00348\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Pharmacology & Translational Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1021/acsptsci.4c00348","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Translational Preclinical PET Imaging and Metabolic Evaluation of a New Cannabinoid 2 Receptor (CB2R) Radioligand, (Z)-N-(3-(2-(2-[18F]Fluoroethoxy)ethyl)-4,5-dimethylthiazol-2(3H)-ylidene)-2,2,3,3-tetramethylcyclopropane-1-carboxamide
We have previously developed seven fluorinated analogues of A-836339 as new PET tracers for cannabinoid type 2 receptor (CB2R) imaging, among which (Z)-N-(3-(2-(2-[18F]fluoroethoxy)ethyl)-4,5-dimethylthiazol-2(3H)-ylidene)-2,2,3,3-tetramethylcyclopropane-1-carboxamide ([18F]FC0324) displayed high affinity and selectivity for CB2R in healthy rats. In the present study, we have further evaluated the imaging and metabolic properties of [18F]FC0324 in a rat model of human CB2R overexpression in the brain (AAV-hCB2) and in non-human primates (NHPs). Autoradiography with AAV-hCB2 rat brain sections exhibited a signal of [18F]FC0324 8-fold higher in the ipsilateral region than in the contralateral region. Blocking with NE40, a CB2R-specific agonist, resulted in a 91% decrease in the radioactivity. PET experiments showed a signal 7-fold higher in the ipsilateral region, and the specificity of [18F]FC0324 for hCB2R in vivo was confirmed by the 80% decrease after blocking with NE40. In NHPs, brain time-activity curves displayed a fast and homogeneous distribution followed by a rapid washout, in accordance with the low amount of CB2Rs in healthy brain. Whole-body PET-CT suggested a high and specific uptake of the radiotracer in the spleen, a CB2R-rich organ, and in the organs involved in metabolism and excretion, with a low bone uptake. In vitro metabolism with monkey liver microsomes (MLMs) led to the formation of six main hydroxylated metabolites of FC0324. Five of them were produced by human liver microsomes, being much less active than MLMs. In vivo, in NHPs, the main radiometabolite was likely to result from further oxidation of hydroxylated compounds, and parent [18F]FC0324 accounted for 8 ± 3% of plasma radioactivity (at 120 min p.i.) with a low level of potential interfering radiometabolites. Furthermore, this metabolism should be significantly reduced in humans due to species differences. In conclusion, [18F]FC0324 appears to be a promising candidate for further human studies with suitable kinetics, selectivity, and metabolic profile for CB2R PET imaging.